Assessment of prognostic factors in follicular lymphoma patients

Eisei Kondo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Prognostic factors, including clinical, biological, and histological parameters, were assessed for 94 patients with follicular lymphomas at our institute. Follicular lymphomas constituted 7.7% (94/1208) of malignant lymphomas in this study. Eighteen patients were diagnosed with stage I follicular lymphoma, 20 with stage II, 23 with stage III, and 33 with stage IV. The cases of follicular lymphoma were subclassified as: follicular small cleaved cell lymphoma (FSC) in 20 cases, follicular mixed cell lymphoma (FMX) in 59 cases, and follicular large cell lymphoma (FLC) in 15 cases. The patients comprised 49 men and 45 women with a median age of 54 years (range, 25-84 years).The complete response rate was 76.5%, and the median survival time was 13 years. The expected 10-year overall survival and event-free survival rates were 61.9% and 38.2%, respectively. Univariate analysis identified the factors associated with poor survival as elevated serum lactate dehydrogenase (LDH) level (P <.0001), age of >60 (P <.0001), Ann Arbor stage III/IV (P <.01), and Eastern Cooperative Oncology Group performance status (PS) of 2 to 4 (P = .048). Multivariate analysis showed that LDH, age, and PS were independent predictors. After application of the International Prognostic Index (IPI), the 10-year survival rates for the low-risk, low-intermediate risk, high-intermediate risk and high-risk groups were 80.4%, 48.7%, 21.9%, and 0.0%, respectively.The differences among these groups were significant at P <.01. The IPI for aggressive non-Hodgkin's lymphoma was found to be applicable to survival prediction for Japanese follicular lymphoma patients.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalInternational Journal of Hematology
Volume73
Issue number3
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Follicular Lymphoma
Survival
L-Lactate Dehydrogenase
Survival Rate
Non-Hodgkin's Lymphoma
Statistical Factor Analysis
Disease-Free Survival
Lymphoma
Multivariate Analysis
Serum

Keywords

  • Follicular lymphoma
  • International prognostic index
  • Prognostic factor

ASJC Scopus subject areas

  • Hematology

Cite this

Assessment of prognostic factors in follicular lymphoma patients. / Kondo, Eisei.

In: International Journal of Hematology, Vol. 73, No. 3, 2001, p. 363-368.

Research output: Contribution to journalArticle

@article{48a39ed72308493bba1e3816aa9bde54,
title = "Assessment of prognostic factors in follicular lymphoma patients",
abstract = "Prognostic factors, including clinical, biological, and histological parameters, were assessed for 94 patients with follicular lymphomas at our institute. Follicular lymphomas constituted 7.7{\%} (94/1208) of malignant lymphomas in this study. Eighteen patients were diagnosed with stage I follicular lymphoma, 20 with stage II, 23 with stage III, and 33 with stage IV. The cases of follicular lymphoma were subclassified as: follicular small cleaved cell lymphoma (FSC) in 20 cases, follicular mixed cell lymphoma (FMX) in 59 cases, and follicular large cell lymphoma (FLC) in 15 cases. The patients comprised 49 men and 45 women with a median age of 54 years (range, 25-84 years).The complete response rate was 76.5{\%}, and the median survival time was 13 years. The expected 10-year overall survival and event-free survival rates were 61.9{\%} and 38.2{\%}, respectively. Univariate analysis identified the factors associated with poor survival as elevated serum lactate dehydrogenase (LDH) level (P <.0001), age of >60 (P <.0001), Ann Arbor stage III/IV (P <.01), and Eastern Cooperative Oncology Group performance status (PS) of 2 to 4 (P = .048). Multivariate analysis showed that LDH, age, and PS were independent predictors. After application of the International Prognostic Index (IPI), the 10-year survival rates for the low-risk, low-intermediate risk, high-intermediate risk and high-risk groups were 80.4{\%}, 48.7{\%}, 21.9{\%}, and 0.0{\%}, respectively.The differences among these groups were significant at P <.01. The IPI for aggressive non-Hodgkin's lymphoma was found to be applicable to survival prediction for Japanese follicular lymphoma patients.",
keywords = "Follicular lymphoma, International prognostic index, Prognostic factor",
author = "Eisei Kondo",
year = "2001",
language = "English",
volume = "73",
pages = "363--368",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Assessment of prognostic factors in follicular lymphoma patients

AU - Kondo, Eisei

PY - 2001

Y1 - 2001

N2 - Prognostic factors, including clinical, biological, and histological parameters, were assessed for 94 patients with follicular lymphomas at our institute. Follicular lymphomas constituted 7.7% (94/1208) of malignant lymphomas in this study. Eighteen patients were diagnosed with stage I follicular lymphoma, 20 with stage II, 23 with stage III, and 33 with stage IV. The cases of follicular lymphoma were subclassified as: follicular small cleaved cell lymphoma (FSC) in 20 cases, follicular mixed cell lymphoma (FMX) in 59 cases, and follicular large cell lymphoma (FLC) in 15 cases. The patients comprised 49 men and 45 women with a median age of 54 years (range, 25-84 years).The complete response rate was 76.5%, and the median survival time was 13 years. The expected 10-year overall survival and event-free survival rates were 61.9% and 38.2%, respectively. Univariate analysis identified the factors associated with poor survival as elevated serum lactate dehydrogenase (LDH) level (P <.0001), age of >60 (P <.0001), Ann Arbor stage III/IV (P <.01), and Eastern Cooperative Oncology Group performance status (PS) of 2 to 4 (P = .048). Multivariate analysis showed that LDH, age, and PS were independent predictors. After application of the International Prognostic Index (IPI), the 10-year survival rates for the low-risk, low-intermediate risk, high-intermediate risk and high-risk groups were 80.4%, 48.7%, 21.9%, and 0.0%, respectively.The differences among these groups were significant at P <.01. The IPI for aggressive non-Hodgkin's lymphoma was found to be applicable to survival prediction for Japanese follicular lymphoma patients.

AB - Prognostic factors, including clinical, biological, and histological parameters, were assessed for 94 patients with follicular lymphomas at our institute. Follicular lymphomas constituted 7.7% (94/1208) of malignant lymphomas in this study. Eighteen patients were diagnosed with stage I follicular lymphoma, 20 with stage II, 23 with stage III, and 33 with stage IV. The cases of follicular lymphoma were subclassified as: follicular small cleaved cell lymphoma (FSC) in 20 cases, follicular mixed cell lymphoma (FMX) in 59 cases, and follicular large cell lymphoma (FLC) in 15 cases. The patients comprised 49 men and 45 women with a median age of 54 years (range, 25-84 years).The complete response rate was 76.5%, and the median survival time was 13 years. The expected 10-year overall survival and event-free survival rates were 61.9% and 38.2%, respectively. Univariate analysis identified the factors associated with poor survival as elevated serum lactate dehydrogenase (LDH) level (P <.0001), age of >60 (P <.0001), Ann Arbor stage III/IV (P <.01), and Eastern Cooperative Oncology Group performance status (PS) of 2 to 4 (P = .048). Multivariate analysis showed that LDH, age, and PS were independent predictors. After application of the International Prognostic Index (IPI), the 10-year survival rates for the low-risk, low-intermediate risk, high-intermediate risk and high-risk groups were 80.4%, 48.7%, 21.9%, and 0.0%, respectively.The differences among these groups were significant at P <.01. The IPI for aggressive non-Hodgkin's lymphoma was found to be applicable to survival prediction for Japanese follicular lymphoma patients.

KW - Follicular lymphoma

KW - International prognostic index

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=0035316246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035316246&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 363

EP - 368

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -